Skip to content

MBX Biosciences

US · MBX #2567 by market cap Listed 2024
49.55 -3.86 -7.23%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 13 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.3 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
117.26% -0.30pp
Institutions
221 +13
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund57.72%
VC/PE Fund35.97%
Hedge Fund20.40%
Individual/Insider2.64%
Public Company2.32%
Insurance Company0.33%
Government Pension Fund0.25%
Private Company0.17%

Top holders as of 2026-09-30

FMR 14.84% · 7.37M sh
Frazier Life Sciences Management, LP 13.40% · 6.65M sh
Wellington Management Group 10.02% · 4.98M sh
New Enterprise Associates, Inc. 7.28% · 3.61M sh
BlackRock 6.99% · 3.47M sh
OrbiMed Advisors LLC 6.19% · 3.07M sh
Paradigm Biocapital Advisors LP 5.05% · 2.51M sh
NVP Associates, LLC 4.30% · 2.14M sh
Deep Track Capital, LP 3.49% · 1.73M sh
Polar Capital Holdings Plc 3.24% · 1.61M sh
Vanguard Capital Management, LLC 3.49% · 1.68M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 30 buys · 19 sells

NameRoleStake
Frazier Life Sciences Management, LP -- 13.40%
Wellington Management Group -- 10.02%
Peter Hawryluk Former Officer 2.45%
Richard Bartram Former Chief Financial Officer 0.10%
Ora Pescovitz Independent Director 0.05%
Steven Hoerter Executive Chairperson, CEO & President 0.04%
Salomon Azoulay Chief Medical Officer 0.00%
Patrick Heron Independent Director --
OrbiMed Advisors LLC -- --
James Cornelius Former Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Steven Hoerter Executive Chairperson, CEO & President Open Market Disposition -4,893 $54.82
2026-11-03 Salomon Azoulay Chief Medical Officer Open Market Disposition -373 $53.96
2026-10-19 Peter Radovich -- Other Derivative Acquisition +18,200 $53.50
2026-08-16 Peter Hawryluk Former Officer Intent to Sell (Form 144) -3,745 $68.29
2026-08-03 Peter Hawryluk Former Officer Intent to Sell (Form 144) -936 $65.77
2026-08-03 Salomon Azoulay Chief Medical Officer Open Market Disposition -370 $65.77
2026-08-02 John Smither Chief Financial Officer Other Acquisition +28,000 --
2026-08-02 John Smither Chief Financial Officer Other Derivative Acquisition +130,000 $64.41
2026-08-02 Steven Hoerter Executive Chairperson, CEO & President Other Acquisition +71,000 --
2026-08-02 Steven Hoerter Executive Chairperson, CEO & President Other Derivative Acquisition +331,000 $64.41
2026-06-09 Richard Bartram Former Chief Financial Officer Intent to Sell (Form 144) -9,167 $30.55
2026-06-08 Richard Bartram Former Chief Financial Officer Intent to Sell (Form 144) -10,833 $29.66
2026-06-03 Patrick Heron Independent Director Other Derivative Acquisition +12,500 $30.91
2026-06-03 Edward Mathers Independent Director Other Derivative Acquisition +12,500 $30.91
2026-06-03 Ora Pescovitz Independent Director Other Derivative Acquisition +12,500 $30.91
2026-06-03 Tiba Aynechi Independent Director Other Derivative Acquisition +12,500 $30.91
2026-06-03 Steven Ryder Independent Director Other Derivative Acquisition +12,500 $30.91
2026-06-03 Steven Hoerter Executive Chairperson, CEO & President Other Derivative Acquisition +12,500 $30.91
2026-06-03 Laurie Stelzer Independent Director Other Derivative Acquisition +12,500 $30.91
2026-05-12 Richard Bartram Former Chief Financial Officer Intent to Sell (Form 144) -15,000 $36.95

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

MBX Biosciences discussion 0 comments

Add a comment